Aptorum Group Limited (APM)
NASDAQ: APM · IEX Real-Time Price · USD
5.63
+0.13 (2.27%)
May 3, 2024, 3:22 PM EDT - Market open
Aptorum Group Revenue
In the year 2023, Aptorum Group had annual revenue of $431.38K, a decrease of -66.71%.
Revenue (ttm)
$431.38K
Revenue Growth
-66.71%
P/S Ratio
53.67
Revenue / Employee
$23,965
Employees
18
Market Cap
23.46M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 431.38K | -864.51K | -66.71% |
| Dec 31, 2022 | 1.30M | -245.89K | -15.95% |
| Dec 31, 2021 | 1.54M | 630.27K | 69.15% |
| Dec 31, 2020 | 911.51K | 376.34K | 70.32% |
| Dec 31, 2019 | 535.17K | 151.72K | 39.57% |
| Dec 31, 2018 | 383.45K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cue Health | 70.94M |
| Exagen | 52.55M |
| Ekso Bionics Holdings | 17.91M |
| Synlogic | 3.37M |
| Sol-Gel Technologies | 1.55M |
| OncoCyte | 1.50M |
| Serina Therapeutics | 142.00K |
| Benitec Biopharma | 61.00K |
APM News
- 3 days ago - Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update - Business Wire
- 2 months ago - Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business - Business Wire
- 4 months ago - Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023 - Business Wire
- 4 months ago - Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders - Business Wire
- 6 months ago - Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 - Business Wire
- 9 months ago - Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets - Business Wire
- 11 months ago - Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma - Business Wire
- 11 months ago - Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris - Business Wire